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The opioid peptide receptors consist of three major subclasses, namely, μ, δ, and κ (MOR,
DOR, and KOR, respectively). They are involved in the regulation of striatal dopamine
functions, and increased opioid transmissions are thought to play a compensatory role
in altered functions of the basal ganglia in Parkinson’s disease (PD). In this study, we used
an immunohistochemistry with tyramide signal amplification (TSA) protocols to determine
the distributional patterns of opioid receptors in the striosome-matrix systems of the rat
striatum. As a most striking feature of striatal opioid anatomy, MORs are highly enriched in
the striosomes and subcallosal streak. We also found that DORs are localized in a mosaic
pattern in the dorsal striatum (caudate-putamen), with heightened labeling for DOR in the
striosomes relative to the matrix compartment. In the 6-hydroxydopamine-lesioned rat
model of PD, lesions of the nigrostriatal pathways caused a significant reduction of striatal
labeling for both the MOR and DOR in the striosomes, but not in the matrix compartment.
Our results suggest that the activities of the striosome and matrix compartments are
differentially regulated by the opioid signals involving the MORs and DORs, and that
the striosomes may be more responsive to opioid peptides (e.g., enkephalin) than the
matrix compartment. Based on a model in which the striosome compartment regulates
the striatal activity, we propose a potent compensatory role of striosomal opioid signaling
under the conditions of the striatal dopamine depletion that occurs in PD.
Keywords: opioid receptors, striosomes, dopamine, Parkinson’s disease, striatum
INTRODUCTION
The mammalian striatum is not a homogeneous structure but
comprises a mosaic organization composed of two functional
subdivisions referred to as the striosomes and the matrix com-
partment (Graybiel, 1990). Neurons in the striosomes and matrix
differ in their content of neurotransmitters and receptors, and
in their afferent and efferent fiber connections, suggesting inter-
dependent striatal functions of the respective compartments
(Graybiel, 1990; Gerfen, 1992). Striosome compartment has been
implicated with motor and behavioral brain functions (for review
see Graybiel, 2008), and their disorders (Graybiel, 1990; Goto
et al., 2010; Crittenden andGraybiel, 2011). Of particular interest,
striosomal opioid signaling has emerged as a potent regulator of
the striatal activities (Miura et al., 2007, 2008) whereas its func-
tional significance in the pathophysiology of movement disorders
remains to be elucidated.
The opioid peptide receptors consist of three major sub-
classes, namely, μ, δ, and κ, which are encoded by the OPRM1,
OPRD1, and OPRK1 genes, respectively (Waldhoer et al., 2004;
Samadi et al., 2006). Both the μ- and δ-opioid receptors
(MORs and DORs, respectively) have an affinity for neuropep-
tide enkephalin, whereas the κ-opioid receptors (KORs) do for
dynorphin (Waldhoer et al., 2004; Samadi et al., 2006). Each type
of opioid receptor is differentially localized in the central ner-
vous system and they are implicated in a broad range of brain
functions (for review see Mansour et al., 1995). Among the brain
regions, the striatum has the highest levels of endogenous opi-
oid peptides and receptors (Mansour et al., 1995; Samadi et al.,
2006). All subtypes of opioid receptors are involved in regulating
dopamine functions in the brain, and opioid transmissions in the
basal ganglia have been implicated in movement disorders such as
Parkinson’s disease (PD) (Bezard et al., 2003; Samadi et al., 2006).
An enhancement of opioid transmission is thought to play a com-
pensatory role in altered functions of the basal ganglia under the
conditions of striatal dopamine depletion in PD (Bezard et al.,
2003; Samadi et al., 2006).
Using immunohistochemistry with tyramide signal amplifi-
cation (TSA) protocols, we here determined the distributional
patterns of opioid receptors in the striosome-matrix systems
of adult rats. We also found that in the 6-hydroxydopamine
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(6-OHDA)-lesioned rat model of PD, lesions of the nigrostri-
atal pathways caused compensatory down-regulation of both the
MORs and DORs in the striosomes, but not in the matrix com-
partment. Our results suggest that the striosomes may be more
responsive to opioid peptides (e.g., enkephalin) than the matrix
compartment. Based on a model in which the striosomes reg-
ulates the striatal activity, we also propose that the striosome
compartment could be an important anatomical substrate in
considering the compensatory roles of enhanced opioid transmis-
sions in PD.
MATERIALS ANDMETHODS
ANIMALS AND SURGERY
All procedures involving experimental animals were approved by
the Ethical Review Committee of the University of Tokushima.
Male Sprague-Dawley rats (9–10-week-old; Nihon SLC Co.,
Shizuoka, Japan) were used. Unilateral lesions of the nigrostriatal
dopamine pathways were introduced in the rats (n = 5) anes-
thetized with pentobarbital (Sigma, St. Louis, MO), by injecting
6-OHDA (10μg in saline containing 0.1% ascorbic acid) into
the medial forebrain bundle under stereotactic guidance (AP
= −4.0mm, ML = −1.3mm, DV = −8.4mm), as previously
reported (Crittenden et al., 2009).
WESTERN BLOTS
Striatal tissues from deeply anesthetized rats were homogenized
in 50mM Tris-HCl buffer, pH 7.5, containing 0.5M NaCl, 0.5%
Triton X-100, 10mMEDTA, 4mMEGTA, 1mMNa3VO4, 30mM
Na4P2O7, 50mM NaF, 0.1mM leupeptin, 0.075mM pepstatin
A, 0.05mg/ml trypsin inhibitor, 1mM phenylmethanesulfonyl
fluoride, 100 nM calyculin A, and 1mM dithiothreitol. After cen-
trifugation at 21,500 × g for 10min, the protein lysates were
resuspended in 100mM NaH2PO4, pH 6.0, 1mM EDTA, 1% 2-
mercaptoethanol, 0.1% sodium dodecyl sulfate, to 1μg/μl final
protein concentration and was heated at 100◦C for 3min. To deg-
lycosylate the opioid receptors, they were then incubated with
Endo-β-N-acetyl-glucosaminidase F1 (Sigma-Aldrich, St. Louis,
MO) at a final concentration of 100 milliunits/ml at 37◦C for
16 h. The deglycosylated protein samples were subjected to the
trans-immunoblots, according to the method that we previously
reported (Yamamura et al., 2013). Specific antibodies against
MOR (1:10,000; Millipore, St. Louis, MO), DOR (1:1000; Abcam,
Cambridge, UK), and KOR (1:1000; Abcam) were used. The
bound antibodies were detected by chemiluminescence staining
(ECL plus kit, GE Healthcare, Buckingham, UK). Staining images
were captured using a lumino-imaging analyzer LAS-4000 (Fuji,
Tokyo, Japan).
TISSUE PREPARATION AND IMMUNOHISTOCHEMISTRY
Rats with unilateral lesions of the nigrostriatal dopamine path-
ways (n = 5) and normal control rats (n = 5) were used. They
were injected intraperitoneally with a lethal dose of pentobarbi-
tal (Sigma), and were then transcardially perfused with 0.01M
phosphate-buffered saline (PBS) at pH 7.4, followed by cold 4%
paraformaldehyde in 0.1M phosphate buffer (PB) at pH 7.4. The
brains were removed, post-fixed overnight in the same fixative
at 4◦C, and stored in a 10-30% sucrose gradient in 0.1M PB at
4◦C for cryoprotection. Sections were cut on a cryostat at 20μm-
thickness, and stored in PBS containing 0.05%NaN3 until use. By
using the TSA method, immunostaining was performed on free-
floating sections (Okita et al., 2012). Rabbit polyclonal antibodies
against MOR (1:100,000; Millipore), DOR (1:10,000; Abcam),
KOR (1:10,000; Abcam), tyrosine hydroxylase (TH; 1:100,000)
(Sato et al., 2008), and Met-enkephalin (1:50,000; Millipore)
were used as primary antibodies. The bound primary antibodies
were detected by the Histofine Simple Stain Kit (Nichirei, Tokyo,
Japan) and the TSA-system with Cyanine3 or Fluorescein (Perkin
Elmer, Shelton, CT). For double labeling, the striatal sections were
first stained for MOR using the TSA-system with Fluorescein.
To remove the bound antibodies, the stained sections were then
incubated in 0.1M glycine-HCl, pH 2.2, for 30min. After rinsing
with PBS for 1 h, they were labeled for DOR or KOR using the
TSA-system with Cyanine3.
DIGITAL IMAGING AND DENSITOMETRIC ANALYSES
Digital microscopy images were captured using an Olympus
BX51 microscope (Olympus, Tokyo, Japan), imported into Adobe
Photoshop CS4, and processed digitally for adjustments of con-
trast, brightness, and color balance. To estimate the density of
MOR, DOR, and KOR labeling, the immunostaining of the stri-
atal sections with these antibodies was simultaneously carried out
in parallel using the same protocols. By means of Meta Morph
(Meta Imaging Series 7.0; Molecular Devices, Tokyo, Japan), the
optical densities of immunoreactive products were measured as
gray levels on non-colored digital images of striosome and matrix
areas in the dorsal striatum, as we previously reported (Sato et al.,
2008). For each animal (n = 5), measurements were made in 5
dorsal striatal fields at the level of +0.5 to −0.2mm from bregma
according to the atlas of Paxinos andWatson (1997). When strio-
somes were not clearly visible, they were identified by comparison
with the sections doubly stained for MORs.
STATISTICAL ANALYSIS
All experimental values were expressed as means ± S.E.M.
Statistical significance was evaluated by the Mann–Whitney
U-test. The significance level was set at P < 0.05.
RESULTS
CHARACTERIZATION OF ANTIBODIES AGAINST MOR, DOR, AND KOR
In this study, we used polyclonal antibodies against C-terminal
synthetic peptides for MOR, DOR, and KOR (Table 1). On the
immunoblots of rat striatal extracts after the deglycosylation
treatment using Endo-β-N-acetyl-glucosaminidase F1 (Garzon
et al., 1995; Chen et al., 2006; Leskelä et al., 2007), main pro-
tein bands with an approximate molecular mass of ∼40 kDa,
corresponding to the predicted size of the native MOR, DOR,
and KOR proteins (Mansour et al., 1995; Waldhoer et al., 2004),
were identified (Figure 1). With these antibodies, single-label
TSA immunohistochemistry showed heightened immunoreactiv-
ity for MOR, DOR, and KOR in the superficial layers of the
dorsal horn in the spinal cord (Figures 1B–D), as in a previous
report of Schulz et al. (1998). No specific immunoreactivity was
found in the spinal cord section processed for the TSA protocols
when these antibodies were omitted (Figure 1E). MOR, DOR,
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and KOR-like immunoreactivity is applied toward all the results,
whereas the term “like” is omitted for simplicity.
NEOSTRIATAL MOSAIC DISTRIBUTION OF MORs AND DORs
We conducted TSA immunohistochemistry to determine the dis-
tributional patterns of MORs, DORs, and KORs in the striosome-
matrix systems of the rat striatum. Obviously, MOR labeling
exhibited a striking mosaic distribution with being highly con-
centrated in the striosomes and subcallosal streak (Figure 2A)
(Pert et al., 1976; Herkenham and Pert, 1981). Similarly, DOR
immunoreactivity was also distributed in a “patchy” manner
in the striatum (Figure 2B). This mosaic distribution of DORs
was found in frontal sections from anterior to posterior of the
Table 1 | Antibodies against opioid receptors used for
immunohistochemistry.
Antibody to Immunogen Source Dilution
μ-opioid
receptor (MOR)
Synthetic peptide
for the C-terminus
of rat μ-opioid
receptor
Millipore
(St. Louis, MO)
Rabbit polyclonal
antibody
No. AB5511
1:100,000
δ-opioid
receptor (DOR)
Synthetic peptide
for amino acids
358–372 of rat
δ-opioid receptor
Abcam
(Cambridge, UK)
Rabbit polyclonal
antibody
No. Ab10272
1:10,000
κ-opioid
receptor (KOR)
Synthetic peptide
for amino acids
366–380 of human
κ-opioid receptor
Abcam
(Cambridge, UK)
Rabbit polyclonal
antibody
No. Ab10283
1:10,000
striatum (Figure 3). When sections were co-labeled for MORs,
the DOR patches localized to the striosomes and subcallosal
streak identified by MOR immunostaining (Figure 4). However,
the DOR patches were obscure in the ventral striatum that
includes the nucleus accumbens (Figures 2B and 3). A high-
power microscopic image of the striosomal cells stained for
the DORs (Figure 4F) showed preferential localization of DOR
labeling in their cytoplasm (soma), as consistent with a previ-
ous study (Wang and Pickel, 2001). These findings indicate that
striosomes and matrix differ in their content of DORs, which
results in the enrichment of DORs in the striosome compartment
in the dorsal striatum. We also examined the striatal localiza-
tion pattern of KORs, and found that KOR labeling was virtu-
ally homogeneous throughout the dorsal and ventral striatum
(Figure 2C).
DOPAMINE DEPLETION REDUCES STRIOSOMAL MOR AND DOR
LABELING
To test the possible interactions between opioid receptors and
dopamine depletion in the striatum, we next produced rats
(n = 5) with unilateral 6-OHDA lesions of the nigrostriatal
pathways. Following 3 weeks of recovery, the striatal sections
were prepared and processed for immunohistochemical stain-
ing. Figures 5A,B illustrates the unilateral lesion of the nigros-
triatal dopamine system as demonstrated by the severe loss
of labeling for TH, the rate-limiting enzyme in dopamine
synthesis, in the lesioned striatum. Optical density measure-
ments revealed a marked (>95%) depletion of TH labeling
in the lesioned striatum compared to the non-lesioned stria-
tum (Figure 5C; P < 0.001, Mann–WhitneyU-test). By contrast,
Met-enkephalin labeling was increased in the lesioned striatum
relative to the non-lesioned striatum (Figures 5D,E), as consis-
tent with a previous report (Dacko and Schneider, 1991). Optical
density measurements revealed a significant difference in striatal
FIGURE 1 | Characterization of antibodies against opioid receptors.
(A) Rat striatal extracts (10μg of protein) treated with
Endo-β-N-acetyl-glucosaminidase F1 (100 milliunits/ml) (see Materials
and Methods) were subjected to trans-immunoblots using the
antibodies against MOR, DOR, and KOR. Arrows indicate
immunoreactive protein bands. MW, molecular weight; PS, protein
staining. (B–D) Single-label TSA immunostaining of the upper cervical
spinal cord by using the antibodies against MOR (B), DOR (C), or
KOR (D). Arrows indicate the superficial layers of the dorsal horn of
the spinal cord. (E) No specific immunoreactivity was found in the
spinal cord processed for the TSA protocols in the absence of the
primary antibodies. Scale bar = 500μm.
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FIGURE 2 | Distributional patterns of MOR, DOR, and KOR in the
striosome-matrix systems of the rat striatum. Single-label TSA
immunostaining of the striatum using the antibody against MOR
(A), DOR (B) or KOR (C). Asterisks indicate examples of the
striosomes, and arrows do the subcallosal streak. Scale bars =
500μm.
FIGURE 3 | Striatal patches identified by DOR-immunostaining in the rat striatum. The frontal sections from anterior to posterior of the striatum labeled
for DOR (A–C) and their color-converted images (D–F). CP, caudate-putamen; NAc, nucleus accumbens; GP; globus pallidus. Scale bars = 500μm.
Met-enkephalin between the lesioned and the non-lesioned sides
(Figure 5F; P < 0.01, Mann–Whitney U-test).
In agreement with previous studies using the 6-OHDA
rat model (Bowen et al., 1982; Johansson et al., 2001), our
present study also revealed a reduction of MOR labeling in the
dopamine-depleted striatum (Figure 6A). However, it was appar-
ently found in the striosomes and subcallosal streak, but not in
the matrix compartment. Similarly, the DOR patches decreased
their staining intensities, and thereby, they were obscure in the
dorsal striatum on the lesioned side (Figure 6C). These visual
impressions were confirmed by quantitative densitometric analy-
ses of immunostained sections. As compared to the non-lesioned
striatum, a statistically significant reduction in the levels of stain-
ing densities for MOR (Figure 6B; P < 0.005, Mann–Whitney
U-test) and DOR (Figure 6D; P < 0.01, Mann–Whitney U-test)
was noted in the striosomes, but not in the matrix, on the
lesioned side. By contrast, striatal KOR labeling did not signif-
icantly differ between the non-lesioned and lesioned striatum
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FIGURE 4 | Compartmental and cellular localization of DORs in the
rat striatum. (A,B) Representative images of striatal sections
double-stained for MOR (A) and DOR (B). Asterisks indicate a
corresponding striosome, and arrows do the subcallosal streak. (C–E)
Photomicrographs of the striosomes (arrows) double-stained for MOR (C)
and DOR (D), with merged image (E). DOR labeling is more highly
concentrated in the striosomes than in the matrix, although both the
compartments contain many cells labeled for DOR. (F) A high-power
photomicrograph of striosomal cells stained for DORs (arrows). Scale bar:
(A,B), 500μm; (C–E), 100μm; (F), 10μm.
(Figures 6E,F). Microscopic observations (Figures 7A–F) also
showed that dopamine depletion resulted in reduced labeling of
DORs, as well as MORs, in the striosomes in the dorsal stria-
tum. Under these conditions in the dorsal striatum, DOR staining
was diffusely distributed, as was KOR staining. These findings are
summarized in Figure 7G.
DISCUSSION
In this study, we employed the TSA immunohistochemistry
to show the distributional patterns of opioid receptors in the
striosome-matrix systems of the rat striatum. Our results showed
that like MORs, DORs were highly concentrated in the strio-
somes, showing a compartmentalized distribution in the dorsal
striatum. This notion corroborates with an earliest study using
the receptor-binding assay (Bowen et al., 1982), although many
subsequent studies have shown a non-patchy and homogeneous
distribution of DORs in the striatum, as determined by the
receptor-binding (McLean et al., 1986; Mansour et al., 1987;
Johansson et al., 2001), in situ hybridization (Mansour et al.,
1993; Le Moine et al., 1994), and immunohistochemical (Cahill
et al., 2001; Wang and Pickel, 2001) assay. On one hand, our
data also showed that KOR labeling was virtually homogeneous
throughout the striatum. This finding corroborates previous
immunohistochemical data (Mansour et al., 1996), but it con-
tradicts the results of a receptor-binding assay (Johansson et al.,
2001). We posit that these inconsistent results might depend on
the differential assay systems used in individual experiments.
As striatal neurons synthesize and locally express opioid recep-
tors, in particular, MORs and DORs (Mansour et al., 1987, 1994;
Guttenberg et al., 1996), our results revealed that striosomal cells
exhibited strong DOR-labeling in their cytoplasm. However, pre-
vious electron microscopic immunocytochemical studies showed
that in striatal patches, DORs are also present in the axon ter-
minals that form symmetric synapses, suggesting that DORs play
a role in modulating the presynaptic release of excitatory amino
acids such as glutamate (Wang and Pickel, 2001). This is sup-
ported by electrophysiological evidence that the DOR agonists
inhibit glutamatergic inputs to medium spiny neurons (MSNs) by
acting at presynaptic sites in the striatum (Jiang and North, 1992;
Blomeley and Bracci, 2011). It is therefore suggested that in stri-
atal patches, DORs are present not only in the striosomal cells and
their local projections but also in the corticostriatal afferent nerve
terminals, as are MORs (Jiang and North, 1992; Wang and Pickel,
2001; Blomeley and Bracci, 2011). At the cellular level, MORs
are present largely in the MSNs bearing dopamine D1 receptors
(D1Rs) in the striosomes (Delfs et al., 1994; Guttenberg et al.,
1996; Georges et al., 1999; Wang et al., 1999). It remains unclear
whether DORs are colocalized with MORs in such a subset of
striosomal MSNs. Given that striosomes are enriched in both the
MORs and DORs relative to the matrix, our findings indicate a
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FIGURE 5 | Rat model with unilateral 6-OHDA lesions of the nigrostriatal
pathways. (A,B) A representative image of the forebrain sections
immunostained for TH. Severe loss of TH-immunoreactive afferents is found in
the lesioned striatum (Lesion) compared to the non-lesioned striatum
(Non-Lesion). Its color-converted image is shown in (B). The intensity of the
labeling is shown in a standard pseudocolor scale from blue (lowest labeling) to
white (highest labeling) through green, yellow, and red. (C)Optical density
measurements of striatal TH labeling in the lesioned striatum (Lesion) (n = 25)
compared to the non-lesioned striatum (Non-Lesion) (n = 25). Values are
means ± S.E.M. ∗P < 0.001 (Mann–Whitney U-test), Non-Lesion vs. Lesion.
(D,E) A representative image of the forebrain sections stained for
Met-enkephalin (MEnk). An increase in striatal Met-enkephalin labeling is found
on the lesioned side (Lesion) compared to the non-lesioned side (Non-Lesion).
Its color-converted image is shown in (E). The intensity of the labeling is shown
in a standard pseudocolor scale. (F)Optical density measurements of striatal
Met-enkephalin labeling in the lesioned striatum (Lesion) (n = 25) compared to
the non-lesioned striatum (Non-Lesion) (n = 25). Values are means ± S.E.M.
∗P < 0.01 (Mann–Whitney U-test), Non-Lesion vs. Lesion.
compartmental difference in the regulation of opioid signaling by
these opioid receptors. This, in turn, suggests the striosomes may
be more responsive to opioid peptides (e.g., enkephalin) than the
matrix compartment.
It has so far been disputed that in PD, an enhancement of opi-
oid transmission might play a compensatory role in altered func-
tions of the basal ganglia (Bezard et al., 2003; Samadi et al., 2006).
However, the precise mechanism by which the increased opioid
signaling modulates the basal ganglia activity is still under debate.
One of the most recognized models of functional organization of
the basal ganglia indicates a key role for balance in the activity of
the twomajor striatal output pathways, i.e., the direct and indirect
pathways (Alexander and Crutcher, 1990). Dopamine depletion
is known to cause increased opioid transmission in the striatum
(Miura et al., 2008). Strikingly, this is found in MSNs that form
the indirect pathway (the indirect-pathway MSNs); the level of
expression of enkephalin and preproenkephalin (PPE)-A mRNA is
increased in the indirect-pathway MSNs (Morissette et al., 1999;
Quik et al., 2002;Meissner et al., 2003), whereas that of dynorphin
and PPE-B mRNA was unaltered or decreased in the direct-
pathway MSNs (Cenci et al., 1998; Meissner et al., 2003). The
pronounced upregulation of enkephalin in the indirect-pathway
MSNs can cause a compensatory down-regulation of both MORs
andDORs in their target cells (Höllt, 1986). This agrees with find-
ings that prolonged activation of MORs and DORs by the opioid
ligand (i.e., enkephalin) promotes their proteolytic degradation
process that contributes to homeostatic regulation of cellular
opioid responsiveness (Henry et al., 2011; Hislop et al., 2011).
Indeed, we here showed a striking reduction of both the MORs
and DORs in the 6-OHDA lesioned striatum that exhibited the
increased level of expression of enkephalin, as consistent with pre-
vious studies (Bowen et al., 1982; Trovero et al., 1990; Smith et al.,
1993; Johansson et al., 2001; Jabourian et al., 2007). However, our
immunohistochemical data also revealed that it was significantly
found in the striosomes, and suggest the possibility that the strio-
some compartment might implicate with the compensatory role
of increased opioid transmissions in PD.
There is a large body of evidence suggesting that strioso-
mal MSNs may be unique among striatal cells in sending their
GABAergic projections directly to the substantia nigra pars com-
pacta (SNc), which contains dopamine-producing cells (DA-cells)
that project back to both the striosome and matrix compart-
ments (see Figure 8A) (Gerfen, 1984; Jimenez-Castellanos and
Graybiel, 1989; Tokuno et al., 2002; Fujiyama et al., 2011). They
also reportedly innervate specifically the regions of the GPi (i.e.,
the ventral pallidum intermediate) that in turn project to the
lateral habenula, which can inhibit the activity of DA-cells in
the SNc (Herkenham and Nauta, 1979; Christoph et al., 1986; Ji
and Shepard, 2007; Matsumoto and Hikosaka, 2007; Bromberg-
Martin et al., 2010). Thus, the striosome compartment could be
in a position to exert global control over dopamine signaling
in the dorsal striatum (Crittenden and Graybiel, 2011). Given
the general inhibitory effect of opioid peptides (Samadi et al.,
2006), increased opioid activities due to dopamine depletion
in the striosomes may reduce the GABAergic (inhibitory) out-
puts of striosomal cells. This would effectively disinhibit and
activate the residual DA-cells in the SNc to increase dopamine
release in the striatum. We thus hypothesize that enhanced opioid
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FIGURE 6 | Loss of striosomal labeling for MOR and DOR in rats with
unilateral 6-OHDA lesions of nigrostriatal pathways. (A) A representative
image of the forebrain sections stained for MOR. (B)Optical density
measurements of MOR labeling in the striosomes and matrix compartment in
the dorsolateral portions of the non-lesioned (Non-Lesion) and lesioned (Lesion)
striatum. Data are mean ± S.E.M. (bars) values (n = 25). ∗P < 0.005
(Mann–Whitney U-test), Non-Lesion vs. Lesion. N.D. indicates no statistically
significant difference (P > 0.05, Mann–Whitney U-test) between Non-Lesion
and Lesion. (C) A representative image of the forebrain sections stained for
DOR. (D)Optical density measurements of DOR labeling in the striosomes and
matrix compartment in the dorsal striatum of the non-lesioned (Non-Lesion)
and lesioned (Lesion) striatum. Data are mean ± S.E.M. (bars) values (n = 25).
∗P < 0.01 (Mann–Whitney U-test), Non-Lesion vs. Lesion. N.D. indicates no
statistically significant difference (P > 0.05, Mann–Whitney U–test) between
Non-Lesion and Lesion. (E) A representative image of the forebrain sections
immunostained for KOR. No apparent difference in striatal KOR-labeling is
found between the non-lesioned (Non-Lesion) and lesioned (Lesion) sides.
(F)Optical density measurements of KOR labeling in the striosomes andmatrix
compartment in the dorsal striatum of the non-lesioned (Non-Lesion) and
lesioned (Lesion) striatum. Data are mean ± S.E.M. (bars) values (n = 25). N.D.
indicates no statistically significant difference (P > 0.05, Mann–Whitney
U-test) between Non-Lesion and Lesion. Scale bars = 500μm.
transmission in the striosomes could exert a compensatory role
via the striosome-SNc pathways in the parkinsonian state.
Striosomes are also thought to communicate with the matrix
compartment via striatal interneurons that include cholinergic
interneurons, GABAergic fast-spiking interneurons containing
parvalbumin, and GABAergic low-threshold spiking interneu-
rons containing nitric oxide synthase, somatostatin and neu-
ropeptide Y (see Figure 8B) (for review see Miura et al., 2008;
Crittenden and Graybiel, 2011). Among these interneurons,
cholinergic cells are particularly interesting because they can
control dopamine release and their overactivity causes motor
impairments in PD (Pisani et al., 2007; Aosaki et al., 2010).
The direct- and indirect-pathway MSNs in the striosomes are
thought to regulate the activities of the matrix MSNs by mod-
ulating acetylcholine release from cholinergic cells (Miura et al.,
2008). Via their synaptic contacts that transmit substance P, the
direct-pathway MSNs could strongly depolarize cholinergic cells
to evoke acetylcholine release (Aosaki et al., 2010). On one hand,
the indirect-pathway MSNs containing enkephalin could presy-
naptically suppress the activities of the direct-pathway neurons by
activating the MORs and DORs on them (Aosaki and Kawaguchi,
1996). Accordingly, in the parkinsonian state, loss of the D1R-
mediated signals could inactivate the direct-pathway MSNs in the
striosomes, thereby reducing acetylcholine release from choliner-
gic cells. Simultaneously, loss of the D2R-mediated signals could
disinhibit and activate the indirect-pathway MSNs to facilitate
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FIGURE 7 | Light microscopic localization of MOR, DOR, and KOR in the
dorsal striatum and its alterations following dopamine depletion. (A–F)
Representative microscopic images of the striatal sections stained for MOR (A
and B), DOR (C andD), and KOR (E and F) on the non-lesioned (A,C, and E) and
lesioned (B,D, andF) sides. Scalebar=200 μm. (G)Summaryofpatterned loss
of striatal labeling for MOR, DOR, and KOR under the conditions of dopamine
depletion. In normal controls, a heightened labeling for MORs or DORs is found
in the striosomes (S). Striatal dopamine depletion causes marked reduction of
MOR- and DOR-labeling in the striosomes, but not in the matrix compartment
(M). Neuronal cell bodies labeled for DOR or KOR are indicated by small dots.
FIGURE 8 | Neural circuits based on the striosome compartment. (A)
Model of the striosome-SNc pathways. SNc, substantia nigra pars compacta;
DA-cells, dopamine-producing cells; VPI, ventral pallidum intermediate; LHb,
lateral habenula. (B) Model of the intercompartmental communication via
striatal interneurons. D1, dopamine D1 receptor; D2, dopamine D2 receptor;
GPe, globus pallidus externa; STN, subthalamic nucleus; GPi, globus pallidus
internus; SNr, substantia nigra pars reticulata; PV, parvalbumin; Ach,
acetylcholine; NOS, nitric oxide synthase.
enkephalin release, leading to further inactivation of the direct-
pathway MSNs. Moreover, the increased opioid transmission in
the striosomes also may directly reduce striatal cholinergic activ-
ity because enkephalin can hyperpolarize cholinergic cells by
activating their DORs and then stop acetylcholine release (Jiang
and North, 1992). Collectively, we suggest that enhanced opioid
signaling in the striosome compartment may also exert a com-
pensatory role by reducing the activity of cholinergic cells in
PD.
In conclusion, we here showed that in the dorsal striatum
of rats, the striosome compartment is enriched in both the
MORs and DORs, suggesting that the striosomes might be more
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responsive to opioid peptides (e.g. enkephalin) than the matrix
compartment. This notion is in accordance with the present
finding that in the 6-OHDA model of PD, compensatory down-
regulation of MORs and DORs occurs in the striosomes. Based
on a model in which the striosome compartment regulates the
activity of the matrix compartment that plays a major role
in the striatal output systems, we hypothesize that striosomal
opioid signaling could exert a potent compensatory regula-
tion of the matrix activity via striosome-SNc projections and
intercompartmental communication. A further understanding
of the cellular and molecular mechanisms involved in strioso-
mal opioid signaling might provide novel strategies to treat PD
and associated motor complications such as levodopa-induced
dyskinesia.
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